Noxopharm (NOX:ASX) today releases a videotaped FNN interview with CEO, Dr Graham Kelly, on the subject of an announcement made to the market on 29 August 2017.
That earlier announcement related to the Company’s intention to extend the use of its frontline experimental anti-cancer drug, NOX66, to the treatment of brain cancer. The announcement referred to pre-clinical data which the Company considers highly relevant to, and potentially unique in the quest for better treatment outcomes for adults and children with cancer of the brain.
The interview is designed to explain what the Company sees as the potential clinical significance of the data.
For further information please download PDF attached:
Download this document
